Technology Networks features Abselion in discussion on advancing AAV quantification
Technology Networks has published a new interview with Abselion Founder & CEO Dr Ruizhi Wang, exploring the challenges of AAV capsid quantification and the need for more accessible, reliable tools in gene therapy development.
In the piece, Dr Wang discusses how approaches like the Amperia™ platform can help simplify AAV measurement and support more consistent, data-driven decisions in early-stage development.
Read the full article here.